만성 바이러스성 B형 간염 환자에서 HBeAg이 혈청전환된 1례

키워드

참고문헌 (36)

1. Chan Ho Park, "Treatment of Solitary Extramedullary Plasmacytoma of the Stomach with Endoscopic Submucosal Dissection", Gut and Liver, 3(4), pp.334~337 (2009), 거트앤리버 발행위원회
2. Song IS, "Seasonal and annual variations on occurrence of HBsAg and acquisition of anti-HBs in Korea", Korean J Intern Med, 22, pp.1007~1015 (1979)
3. Korea Centers for Disease Control and Prevention, "2006 Disease Control White Paper", pp.144~ (2007), Korea Centers for Disease Control and Prevention
4. Lee BS, "Nationwide seroepidemiology of hepatitis B virus infection in South Korea in 2009 emphasizes the coexistence of HBsAg and anti-HBs", J Med Virol, 85 (2013)
5. The Fourth Korea National Health and Nutrition Examination Survey (KNHANES IV), 2010. Health Examination, "Ministry of Helalth & Welfare KCfDCaP", Ministry of Helalth &Welfare, ~ (2012)
6. Chae HB, "Current status of liver diseases in Korea: hepatitis B", Korean J Hepatol, 15(Suppl 6), pp.S13~S24 (2009)
7. 천재희, "단일 기관에서 치료한 간세포암종 1,078예의 임상 백서", Clinical and Molecular Hepatology, 10(2004), pp.288~297 (2004), 대한간학회
8. Kim SR, "Organizing Committee of Japan-Korea Liver Symposium. Epidemiology of hepatocellular carcinoma in Japan and Korea", Oncology, 75(Suppl 1), pp.13~16 (2008)
9. Si Hyun Bae, "Hepatitis B Virus Genotype C Prevails Among Chronic Carriers of the Virus in Korea", Journal of Korean Medical Science, 20(5), pp.816~820 (2005), 대한의학회
10. Kim H, "Molecular epidemiology of hepatitis B virus (HBV) genotypes and serotypes in patients with chronic HBV infection in Korea", Intervirology, 50, pp.52~57 (2007)
11. 이중민, "말디토프 질량 분석을 이용한 한국인의 B형간염 바이러스유전자형 및 임상적 의의에 대한 재평가", Clinical and Molecular Hepatology, 10(2004), pp.260~270 (2004), 대한간학회
12. Livingston SE, "Clearance of hepatitis B e antigen in patients with chronic hepatitis B and genotypes A, B, C, D, and F", Gastroenterology, 133, pp.1452~1457 (2007)
13. The Korean Association for the Study of the Liver, "2015 Chronic Hepatitis B Clinical Practive Guideline", pp.32~72 (2015), Publishing & Printing Co. Jin
14. Manns MP, "Long-term safety and tolerability of entecavir in patients with chronic hepatitis B in the rollover study ETV-901", Expert Opin Drug Saf, 11, pp.361~368 (2012)
15. Koteiche HA, "Structure of the substrate binding pocket of the multidrug transporter EmrE: site-directed spin labeling of transmembrane segment 1", Biochemistry, 42, pp.6099~6105 (2003)
16. Gupta SK, "Tenofovir-associated Fanconi syndrome:review of the FDA adverse event reporting system", AIDS Patient Care STDS, 22, pp.99~103 (2008)
17. Gish RG, "Entecavir therapy for up to 96 weeks in patients with HBeAgpositive chronic hepatitis B", Gastroenterology, 133, pp.1437~1444 (2007)
18. Hong JW, "Study of Korean Medicine Liver System", pp.65~138 (2015), Publishing & Printing Co. Nado
19. Kang KT, "The Effect of Inchinchunggantang-derivative on Mouse Virus Hepatitis(MHV-2M) and Water Immersion Stress", Journal of Kyung Hee University Graduate School, 20(2), pp.133~150 (1997)
20. Park YJ, "The Effect of Injinchunggantang-derivative on Proliferation of Hepatocyte", J Korean Med, 19(1), pp.145~164 (1998)
21. Hong SH, "The Effects of Injinchunggantang-derivative on Cell Viability, Cell Cycle Progression and Apoptosis of Hepatocytes", J Korean Med, 19(2), pp.337~372 (1998)
22. Ko H, "The Effects of 5kinds of Injinsaryung-San fractions on Cell Viablity, Cell Cycle Progression and Fas-mediated Apoptosis of HepG2 Cells", J Korean Med, 21(3), pp.174~185 (2000)
23. Lee JH, "Effects of Five Fractions of Artemisia capillaris THUNB on TGFβ1-induced Apotosis in HepG2 Cells", J Korean Med, 20(1), pp.53~61 (2000)
24. Shin SM, "Effect of Injin Fraction on Hepatic Fibrosis induced by TGF-β1", J Korean Med, 22(3), pp.141~155 (2001)
25. Sim JG, "Prevalence and its changes of hepatitis B viral markers from 1988to 1993 in Korean children", J Korean Pediatr, 38, pp.1535~1539 (1995)
26. Shim JH, "Efficacy of entecavir in treatment-naive patients with hepatitis B virusrelated decompensated cirrhosis", J Hepatol, 52, pp.176~182 (2010)
27. Liaw YF, "Tenofovir disoproxil fumarate (TDF), emtricitabine", TDF, and entecavir in patients with decompensated chronic hepatitis B liver disease, 2011, pp.53, 62~72
28. Osborn M, "Safety and efficacy of entecavir for the treatment of chronic hepatitis B", Infect Drug Resist, 4, pp.55~64 (2011)
29. Tenney DJ, "Long-term monitoring shows hepatitis B virus resistance to entecavir in nucleoside-naive patients is rare through 5 years of therapy", Hepatology, 49, pp.1503~1514 (2009)
30. Manns MP, "Long-term safety and tolerability of entecavir in patients with chronic hepatitis B in the rollover study ETV-901", Expert Opin Drug Saf, 11, pp.361~368 (2012)
31. 장은경, "The Effects of Injincheonggan-tang on Two Patients with HBeAg-Negative Chronic Hepatitis B : Case Report", 대한한의학회지, 35(2), pp.69~78 (2014), 대한한의학회
32. 정윤종, "만성 B형 간염을 동반한 초기 간경변 환자에서 茵蔯淸肝湯 투여 관찰한 5례", 대한한방내과학회지, 27(4), pp.1014~1026 (2006), 대한한방내과학회
33. Kim CG, "Study on the Maternal Serum Alpha-Fetoprotein During Pregnancy", Obstetrics &Gynecology Science, 29(9), pp.1240~1255 (1986)
34. Iloeje UH, "Risk Evaluation of Viral Load Elevation and Associated Liver Disease", Cancer-In HBV (the REVEAL-HBV) Study Group. Predicting cirrhosis risk based on the level of circulating hepatitis B viral load, 2006, pp.130, 678~686
35. Chen CJ, "Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level", JAMA, 295, pp.65~73 (2006)
36. Hsu YS, "Long-term outcome after spontaneous HBeAg seroconversion in patients with chronic hepatitis B", Hepatology, 35, pp.1522~1527 (2002)

관련 논문AI추천